The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Slides:

Advertisements

Similar presentations

Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.

Advertisements

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.

경구용 항응고제와 항혈소판제의 병행치료에 대한 최신 지견

Denise Sutter, PharmD, BCPS

Upfront Combination Therapy vs Step-Up Approach for PAH:

When should aspirin be dropped from triple therapy?

Addressing the Challenges in Primary and Secondary Stroke Prevention

Polypharmacy Anticoagulation: AF meets PCI

on behalf of the RE-DUAL PCI Steering Committee and Investigators

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

(p < for group 1 or 2 vs. group 3)

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

Achieving Long-Term Protection Post-MI

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Access to NOAC Therapy:

Applying New Data in Practice:

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Introduction Antiplatelet Agents ADP Receptor Antagonists.

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

Selecting NOACs for High-Risk Patients

Tailoring Antiplatelet Therapy in PCI

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

The Essentials for Secondary Stroke Prevention

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

Treatment Options to Consider

NOACS: Emerging data in ACS/IHD

AF and PCI in Practice.

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Learning Objectives Metabolic Abnormalities Associated With T2D.

Anticoagulation and Thrombosis Management

Identifying High-Risk AF Patients

Duration of Dual Antiplatelet Therapy

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

CAD and HF Often Coexist

A Case Challenge.

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

Antithrombotics in Arterial Disease: Focus on Coronary Disease

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.

Factor Xa Inhibitors in Coronary Artery Disease

ESC Guideline on the Management of STEMI Recommendation for DAPT

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Program Goal

ESC Guidelines

ACC/AHA Guidelines

RE-DUAL PCI Trial Design

RE-DUAL PCI ISTH Major or CRNM Bleeding

RE-DUAL PCI: Thromboembolic Events, Death, or Unplanned Revascularization

PIONEER AF-PCI Clinically Significant Bleeding

PIONEER AF-PCI Study Design

PIONEER AF-PCI MACE

RE-DUAL PCI TIMI Major Bleeding and ICH

Duration of Triple Therapy Options

Optimal OAC Dose Full Dose vs Reduced Dose

COMPASS Efficacy Outcomes in Stable CAD/PAD

ATLAS ACS 2-TIMI 51 Stent Thrombosis in ACS

P2Y12 Inhibitor in Antithrombotic Regimens Clopidogrel vs Newer Agents

RE-DUAL PCI Subgroup Analysis Clopidogrel vs Ticagrelor

Antithrombotic Strategies for Complex Patients With AF Following PCI

APPRAISE-2 Anticoagulant Therapy After ACS

Danish Registry: Thromboembolic and Bleeding Outcomes Following MI or PCI in Patients With AF

Antithrombotic Strategy Considerations

PIONEER AF-PCI Post Hoc Analysis Recurrent Hospitalization

ENTRUST-AF PCI Study Design

AUGUSTUS Study Design

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)